Physician profile
Karamchand Rameshwar
NPI 1790858678
$3,311.91
in general payments reported to CMS, 2019-2025
14 companies · $810 in 2025
The $810 reported for 2025 was more than what 78% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $699 · 2020: $416 · 2021: $532 · 2022: $308 · 2023: $136 · 2024: $412 · 2025: $810.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,246 · Education: $111.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,245.70 |
| Education | $111.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $597.39 | 2021-2024 | |
| Teva Pharmaceuticals USA, INC. | $585.13 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $576.13 | 2024-2025 | Cobenfy |
| Neurocrine Biosciences, INC. | $252.46 | 2024-2025 | Ingrezza |
| Lundbeck LLC | $250.25 | 2019-2024 | Abilify Asimtufii |
| Otsuka America Pharmaceutical, INC. | $215.94 | 2019-2024 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $214.54 | 2020-2022 | |
| Janssen Pharmaceuticals, INC | $166.88 | 2019-2021 | |
| Alkermes, INC. | $138.84 | 2022-2025 | Aristada, Lybalvi |
| Sunovion Pharmaceuticals INC. | $125.34 | 2019-2022 | |
| Indivior INC. | $71.98 | 2019-2020 | |
| Noven Therapeutics, LLC | $56.72 | 2020-2021 | |
| Allergan, INC. | $43.64 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $16.67 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Karamchand Rameshwar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.